Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market:
https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

According to The Business Research Company’s Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024, The chronic obstructive pulmonary disease (copd) treatment market size has grown strongly in recent years. It will grow from $20.08 billion in 2023 to $21.09 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to smoking epidemic and tobacco use, advancements in inhalation therapies, awareness programs and early diagnosis, government initiatives for respiratory health, research and development in pulmonology.

The chronic obstructive pulmonary disease (copd) treatment market size is expected to see strong growth in the next few years. It will grow to $26.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to personalized medicine and biomarker research, biologic therapies and targeted interventions, air quality concerns and environmental factors, global efforts for smoking cessation, collaborations for drug development. Major trends in the forecast period include digital health solutions for copd management, biologic therapies for copd, emergence of personalized medicine, combination therapies and inhalers, early diagnosis and intervention, pulmonary rehabilitation programs.

The increasing prevalence of lung disease is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease is a disorder that affects the lungs and keeps them from functioning properly. The most common lung diseases are asthma, COPD, and lung cancer. Chronic obstructive pulmonary disease (COPD) treatment is primarily used to treat lung disease, decrease the condition’s progression, control the symptoms, and avoid lung damage by employing inhalers and drugs. For instance, in September 2022, according to the global initiative for Chronic obstructive lung disease (GOLD), a US-based non-profit organization, 3.2 million people per year die from the chronic obstructive pulmonary disease (COPD), which affects an estimated 200 million people. Additionally, asthma affected 262 million people globally in 2022. These numbers are expected to rise in the future. Moreover, in 2023, according to the LUNGevity Foundation, a US-based non-profit organization, due to lung cancer, 127,000 Americans will die in the US each year. Therefore, the increasing prevalence of lung disease is driving the growth of the chronic obstructive pulmonary disease (COPD) treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp

The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –

1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings

Product innovation is a key trend gaining popularity in the chronic obstructive pulmonary disease (COPD) treatment market. Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are focusing on developing innovative products to sustain their position in the market. For instance, in April 2022, GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and biotechnology company, launched Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol), the first single-inhaler triple treatment (SITT) for patients in India with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is used as a maintenance medication to treat and prevent the signs and symptoms of chronic obstructive pulmonary disease (COPD) in people 18 years of age and older. It performs similarly to natural corticosteroid hormones, reducing immune system activity by attaching to receptors (targets) on particular immune cell types. Additionally, it helps reduce swelling of the airways in the lungs to make breathing easier.

The chronic obstructive pulmonary disease (copd) treatment market report table of contents includes:

1. Executive Summary
2.Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Characteristics
3.Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends And Strategies
4.Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Macro Economic Scenario
5.Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size And Growth
6.Chronic Obstructive Pulmonary Disease (COPD) Treatment Segmentation
7.Chronic Obstructive Pulmonary Disease (COPD) Treatment Regional And Country Analysis
.
.
.
27.Chronic Obstructive Pulmonary Disease (COPD) Treatment Competitive Landscape And Company Profiles
28.Chronic Obstructive Pulmonary Disease (COPD) TreatmentKey Mergers And Acquisitions
29.Chronic Obstructive Pulmonary Disease (COPD) Treatment Future Outlook and Potential Analysis